Svas Biosana S.p.A. (BIT:SVS)
Italy · Delayed Price · Currency is EUR 8.00
0.00 (0.00%)
At close: Nov 6, 2026
Svas Biosana Revenue
Svas Biosana had revenue of 3.18M EUR in the half year ending June 30, 2026, a decrease of -94.71%. This brings the company's total for the last twelve months to 72.82M, down -45.48% year-over-year. In the year 2025, Svas Biosana had annual revenue of 142.65M with 16.20% growth. That makes Svas Biosana the 19,145th largest company in the world by revenue and 159th in Italy.
Revenue (ttm)
72.82M
Revenue Growth
-45.48%
P/S Ratio
0.29
Revenue / Employee
393.73K
Employees
360
Market Cap
41.78M
Revenue by Geography
- Italy 67.25M 48.3%
- European Union 47.79M 34.4%
- Non-EU 24.07M 17.3%
Fiscal year ended Dec 31, 2025 See the full Svas Biosana breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 142.65M | 19.89M | 16.20% |
| Dec 31, 2024 | 122.77M | 429.37K | 0.35% |
| Dec 31, 2023 | 122.34M | 20.06M | 19.61% |
| Dec 31, 2022 | 102.28M | 20.76M | 25.47% |
| Dec 31, 2021 | 81.52M | 3.81M | 4.91% |
| Dec 31, 2020 | 77.71M | 2.69M | 3.59% |
| Dec 31, 2019 | 75.01M | 4.94M | 7.05% |
| Dec 31, 2018 | 70.07M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Recordati Industria Chimica e Farmaceutica | 2.71B |
| Amplifon | 2.41B |
| DiaSorin | 1.18B |
| EL.En. | 611.40M |
| GPI S.p.A. | 543.23M |
| Talea Group | 132.17M |
| EuKedos | 52.91M |
| Farmacosmo | 46.23M |